Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients

AIDS

Volumn 16, Issue 12, 2002, Pages 1617-1626

  Palella Jr , Frank J ^a   Chmiel, Joan S ^a   Moorman, Anne C ^b   Holmberg, Scott D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

AIDS; Antiretroviral therapy; Durability of therapy; HAART; Morbidity; Mortality; Predictors of therapeutic response; Response to therapy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL OBSERVATION; COHORT ANALYSIS; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTPATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES; VIREMIA;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMBULATORY CARE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0037119026     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200208160-00007     Document Type: Article

References (17)

1. Declining mortality and morbidity in HIV-infected ambulatory patients
2. Longer-term immunologic effects and side effects of successful antiretroviral therapy
3. How many pills do HIV infected patients take
4. Patient characteristics and attitudes associated with antiretroviral adherence
5. Public health implications of antiretroviral therapy and HIV drug resistance
6. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
7. Factors associated with the successful modification of antiretroviral therapy
8. Changing conditions and therapies of ambulatory HIV-infected patients: The HIV Outpatient Study (HOPS)
9. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
10. Improvement in CD4+ cell counts despite persistently detectable viral loads
11. Sustained CD4+ cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
12. Perspective: Human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: Issues in interim monitoring and early stopping
13. Factors that predict incomplete virologic response to protease inhibitor-based antiretroviral therapy
14. Editorial response: Discordance between virological, immunologic, and clinical outcomes of therapy with protease inhibitors among human immunodeficiency virus-infected patients
15. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-Infected patients with detectable viremia
16. Virologic and regimen terminal surrogate endpoints in AIDS clinical trials